<DOC>
	<DOCNO>NCT02521285</DOCNO>
	<brief_summary>This randomized phase II trial study safety well aspirin work prevent Barrett 's esophagus return successfully eliminate radiofrequency ablation . Studying sample tissue patient Barrett 's esophagus level specific protein link develop Barrett 's esophagus may help doctor learn whether aspirin prevent return successfully treat .</brief_summary>
	<brief_title>Aspirin Preventing Disease Recurrence Patients With Barrett Esophagus After Successful Elimination Radiofrequency Ablation</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To conduct randomize , double blind , placebo-controlled phase II chemoprevention trial , investigate whether supplementation aspirin 325 mg/day 12 month safe reduces expression CDX2 messenger ribonucleic acid ( mRNA ) ( biomarker associate risk develop Barrett 's esophagus [ BE ] ) comparison placebo successful radiofrequency ablation ( RFA ) . SECONDARY OBJECTIVES : I . To assess safety 12 month . II . To assess difference expression CDX2 18 month , activation status NF-kB assessing level total phosphorylated ( phospho ) -p65 cytoplasmic nuclear translocation phospho-p65 likely affect aspirin . III . To assess prostanoid marker , prostaglandin E2 , prostaglandin synthases , know respond aspirin correlation clinicopathological factor esophageal cancer . IV . To assess difference expression proinflammatory cytokine know induce activation NFkB , i.e. , TNFalpha , IL-1beta , IL-6 , IL-10 , IL-17A , IL-23 measure . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive aspirin orally ( PO ) daily ( QD ) 12 month . ARM B : Patients receive placebo PO QD 12 month . After completion study treatment , patient follow 1 , 3 , 6 , 9 , 12 , 18 month .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Known diagnosis histologicallyconfirmed BE without dysplasia ( define presence specialize columnar epithelium anywhere tubular esophagus &gt; = 1 cm circumferential involvement noncircumferential involvement specialize columnar epithelium ) require radiofrequency ablation Documentation complete ablation BE radiofrequency ablation two endoscopic examination least 3 month apart ( include evidence BE surveillance biopsy ) determine pathologist site ; completion ablation occur great 36 month prior randomization Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participate trial , inform research personnel clinical care provider immediately Willingness provide tissue sample research purpose No chronic use aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) selective cyclooxygenase2 ( COX2 ) inhibitor one month prior randomization ; chronic use define aspirin NSAID use &gt; = 7 day one month precede begin randomization Hemoglobin &gt; = 10 g/dL hematocrit &gt; = 30 % Leukocyte count &gt; = 3,000/microliter Platelet count &gt; = 100,000/microliter Absolute neutrophil count &gt; = 1,500/microliter Creatinine = &lt; 2.5 x institutional upper limit normal ( ULN ) OR glomerular filtration rate ( GFR ) &gt; 30 ml/min/1.73 m^2 Total bilirubin = &lt; 2 x institutional ULN Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2.5 x institutional ULN Alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional ULN A negative serum pregnancy test do = &lt; 7 day prior preregistration , woman childbearing potential Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Ability understand willingness sign write informed consent document ; legally authorize representative ( LAR ) may sign informed consent person capacity legally consent take part study Inability abstain , NSAID ( include aspirin ) , selective COX2 inhibitor therapy time randomization completion study ( study period define baseline exit endoscopy 18 month randomization define completion study ) ; participant may take Tylenol nonNSAID pain reliever Current plan use anticoagulant drug : warfarin , heparin , low molecular weight heparin , Plavix , Aggrenox throughout course study Individuals take drug list may randomize unless willing stop medication ( possibly change alternative nonexcluded medication treat condition ) less 3 month prior start aspirin placebo study ; consultation participant 's primary care provider obtain prior stop agent ; use follow drug drug class prohibit aspirin/placebo treatment : NSAIDs : aspirin , Naprosyn , ketorolac others NSAIDs COX2 inhibitor : celecoxib , rofecoxib Valproic acid Sulfinpyrazone Probenecid Corticosteroids ( shortterm use define less 2 week ) Platelet aggregation inhibitor , except monitor antithrombotic regimen Methotrexate ( MTX ) Vaccines contain live virus Gingko Individuals uncontrolled renal insufficiency renal failure Participants prior fundoplication , bariatric surgery major upper gastrointestinal ( GI ) surgery ; cholecystectomy ground exclusion History invasive cancer diagnosis = &lt; 12 month prior randomization , except nonmelanoma skin cancer ; patient T1a adenocarcinoma esophagus arise set Barrett 's esophagus eligible enrollment trial History cancer treatment = &lt; 12 month prior randomization , except hormonal therapy ( except treatment nonmelanoma skin cancer carcinomainsitu cervix ) Receipt investigational agent = &lt; 3 month prior randomization , except innocuous agent know interaction study agent ( e.g. , standard dose multivitamin topical agent limited skin condition ) , discretion Protocol Lead Investigator participate site History allergic reaction attribute aspirin compound similar chemical biologic composition study agent History endoscopically radiographically diagnose peptic ulcer disease upper GI bleeding past 5 year history endoscopically radiographically diagnose peptic ulcer disease upper GI bleeding time take aspirin Uncontrolled intercurrent illness include , limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , bleed disorder , vitamin K deficiency , alcohol abuse ( define ingestion 3 drink per day ) psychiatric illness/social situation would limit compliance study requirement Pregnant woman Breast feed woman Surveillance biopsy demonstrate residual BE qualify exam Presence esophageal stricture define `` recognizable change esophageal luminal caliber accompany symptom dysphagia , asymptomatic narrowing either allow adult endoscope pas allow passage resistance '' Patients human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>